Files and links (1)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Chitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia
Journal of pediatric intensive care, v 9(3)
Sep 2020
PMID: 32685255
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Abstract
Infants born extremely preterm are at a high risk of developing bronchopulmonary dysplasia (BPD) which is characterized by large, simplified alveoli, increased inflammation, disrupted and dysregulated vasculogenesis, decreased cell proliferation, and increased cell death in the lungs. Due to lack of specific drug treatments to combat this condition, BPD and its long-term complications have taken a significant toll of healthcare resources. AVR-25, a novel immune modulator experimental compound, was able to partially recover the pulmonary phenotype in the hyperoxia-induced experimental mouse model of BPD. We anticipate that AVR-25 will have therapeutic potential for managing human BPD.
Metrics
8 Record Views
Details
- Title
- Chitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia
- Creators
- Pragnya Das - Drexel UniversitySuchismita Acharya - University of North Texas Health Science CenterDilip Shah - Drexel UniversityBeamon Agarwal - GenomeRxUS, Secane, Pennsylvania, United StatesVarsha Prahaladan - Drexel UniversityVineet Bhandari - Drexel University
- Publication Details
- Journal of pediatric intensive care, v 9(3)
- Publisher
- Georg Thieme Verlag KG
- Grant note
- AyuVis Research Inc.
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000548246800014
- Other Identifier
- 991019167650304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Pediatrics